原研药与仿制药的药品最高零售限价与药品集中招标采购中标价的差异比较  

Comparative Study on the Differences between the Maximum Retail Price and Purchasing Tender Price of Original and Generic Drugs

作　　者：万曜 刘宝[1] 

机构地区：[1]复旦大学公共卫生学院/健康风险预警治理协同创新中心/卫生部卫生技术评估重点实验室,上海200032

出　　处：《中国药房》2015年第15期2032-2034,共3页China Pharmacy

摘　　要：目的:为深化我国药品价格改革提供参考。方法:通过纳入的抗微生物药物和循环系统药物(94个品规),计算我国2005-2013年原研药与仿制药最高零售限价和药品集中招标采购中标价差率。结果:仿制药最高零售限价与中标价差异大,而原研药最高零售限价与中标价则较为接近。就仿制药而言,抗微生物药的最高零售限价与中标价差率明显高于循环系统药;而就原研药而言,抗微生物药的最高零售限价与中标价差率接近循环系统药。结论:药品最高零售限价与药品集中招标采购中标价并存的格局应逐步转型为以药品集中招标采购中标价为基础的格局。OBJECTIVE： To provide reference for the deepening veform of drugs price in china. METHODS： Based on the 94 antimicrobial and circulatory system drugs, the percentage differences between the maximum retail price and tender price of original and generic drugs from 2005 to 2013 were calculated. RESULTS：The percentage difference between maximum retail price and tender price in generic drugs was large, while the corresponding difference in original drugs was much smaller. Regarding generic drugs, the percentage difference between maximum retail price and tender price for antimicrobial drugs was larger than that for circu- latory system drugs. Regarding original drugs, the percentage difference between maximum retail price and tender price for antimicrobial drugs was similar to that for circulatory system drugs. CONCLUSIONS： The coexistence of maximum retail price and tender price should be gradually changed to a system based on centralized tendering price of drug purchase.

关 键 词：药品最高零售限价 药品集中招标采购 中标价 价格改革 

分 类 号：R95[医药卫生—药学]